A Phase 2 interventional study of LOU064 Arm 1 and LOU064 Arm 2 in Chronic Spontaneous Urticaria, sponsored by Novartis Pharmaceuticals. Completed at 82 sites in 17 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2022-04-29.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing remibrutinib in Chronic Urticaria — 2 open to participants now, 6 under way, 5 of them phase 3. remibrutinib · Chronic Urticaria.
Among the 12 studies testing remibrutinib in Chronic Urticaria, this one is the 7th largest by enrollment, is one of 2 that started in 2019, is one of 3 in phase 2, and was the 1st registered.
197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.
Browse Chronic Urticaria studies →2 of the 12 studies testing remibrutinib in Chronic Urticaria are open now, in 9 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Canada, Hong Kong, Japan and 1 more country
Ages 18+
Novartis Pharmaceuticals · Sites in United States, France, Germany and 2 more countries
Ages 18+
By country, each count listing its studies:
remibrutinib: first FDA approval 2025 (RHAPSIDO), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, remibrutinib is the treatment under test here. Read study by study →
12 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 311 is above the median of 80 across 147 interventional studies indexed under Chronic Urticaria.
Median enrollment 347 across the 12 interventional studies. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 1 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
38 studies in Chronic Urticaria by Novartis: 7 open now, 12 under way, 5 of them phase 3. Of 24 finished, 19 (79%) have results posted.
Among the 38 studies in Chronic Urticaria by Novartis, this one is the 13th largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2019, is one of 8 in phase 2, and was the 15th registered.
Novartis’s Chronic Urticaria studies by the year they started, since 2007.
2 of the studies testing remibrutinib in Chronic Urticaria that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06868212Phase 3Novartis PharmaceuticalsA Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines | 2027-02-22 |
| NCT06865651Novartis PharmaceuticalsStudy of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria | 2027-08-23 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing remibrutinib in Chronic Urticaria, from their registry updates:
Among Novartis’s 38 in Chronic Urticaria:
This tab as a report to print or save as PDF → With an account.
This was a multicenter, randomized, double-blind and placebo-controlled phase 2b dose-finding study to assess the efficacy and safety of LOU064 in adults chronic spontaneous urticaria (CSU) patients inadequately controlled by H1-antihistamines
This was a global Phase 2b multicenter, randomized, double-blind, parallel-group, placebo-controlled study investigating the efficacy, safety and tolerability of six dosing groups of oral LOU064 in subjects with inadequately controlled CSU despite treatment with (second generation) H1-antihistamine. The study comprised of the 7 treatment arms: LOU064 10 mg q.d., LOU064 35 mg q.d., LOU064 100 mg q.d., LOU064 10 mg b.i.d, LOU064 25 mg b.i.d., LOU064 100 mg b.i.d. and placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 mg LOU064 qd capsule once daily
Drug: LOU064 Arm 1
35 mg capsule qd LOU064 once daily
Drug: LOU064 Arm 2
100 mg capsule qd LOU064 once daily
Drug: LOU064 Arm 3
10 mg capsule LOU064 bid
Drug: LOU064 Arm 4
25 mg capsule LOU064 bid
Drug: LOU064 Arm 5
100 mg capsule LOU064 bid
Drug: LOU064 Arm 6
Participants took matching placebo twice daily
Drug: Placebo arm
10 mg LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
35 mg of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
100 mg of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
10mg bid of LOU064 orally, twice daily from Day 1 to 85
25 mg bid of LOU064 orally, twice daily from Day 1 to 85
100 mg bid of LOU064 orally, twice daily from Day 1 to 85
Matching placebo, orally, twice daily from Day 1 to 85
Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 4
UAS7 score change (LS mean Change) from baseline at Week 4 estimated with a mixed-effect repeated measurement analysis of UAS7 score change from baseline (FAS) The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. The maximum UAS7 value is 42. A higher score indicates worse disease. A negative change score (week 4 score minus Baseline score) indicates improvement.
Time frame: Baseline, Week 4
Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12
UAS7 score change (LS mean Change) from baseline at Week 12 estimated with a mixed-effect repeated measurement analysis of UAS7 score change from baseline (FAS)
Time frame: Week 12
Percentage of Participants With Either Complete Absence of Hives and Itch (UAS7=0) or Well-controlled Disease (UAS7<=6)
UAS7=0 and UAS7\<=6 response rate over time by treatment group (non-responder imputation) The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. The maximum UAS7 value is 42. A higher score indicates more severe disease. A negative change score (week 4 score minus Baseline score) indicates improvement.
Time frame: Week 12
Cumulative Number of Weeks With an AAS7=0 Response
The Weekly angioedema activity score (AAS) is a validated tool to assess occurrence of episodes of angioedema. If the subject reports the occurrence of angioedema ("opening question") with "no", AAS score for this day is 0. If "yes" is the answer to the opening question, the subject will continue to answer questions about the duration, severity and impact on daily functioning and appearance of the angioedema. The AAS7 is a weekly AAS score (AAS7). Minimum and maximum possible AAS7 scores are 0-105. Higher score means more severe disease.
Time frame: Baseline to Week 12
Percentage of Participants With DLQI Score of 0 or 1
Percentage of subjects with DLQI 0/1 response by treatment group and visit (non-responder imputation) The Dermatology Life Quality Index (DLQI) is a 10-item dermatology-specific quality of life (QoL) measure. Subjects rate their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives thinking about the previous 7 days. An overall score is calculated and ranges from 0 to 30 (higher score meaning worse disease-related QoL). A DLQI score of 0 or 1 means that there is no impact of a skin disease on the patient's life.
Time frame: Week 4 and Week 12
Mean Change From Baseline in DLQI Score
Summary of DLQI score and change from baseline The Dermatology Life Quality Index (DLQI) is a 10-item dermatology-specific quality of life (QoL) measure. Subjects rate their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives thinking about the previous 7 days. An overall score is calculated and ranges from 0 to 30 (higher score meaning worse disease-related QoL).
Time frame: Baseline, Week 4 and Week 12
Area Under the Blood Concentration-time Curve (AUC) of LOU064
Assessment of the area under the blood concentration-time curve (AUC) up to four hours following oral administration at Week 4 and Week 12 .
Time frame: Week 4 and Week 12
Observed Maximum Blood Concentration (Cmax) of LOU064
Assessment of the observed maximum blood concentration (Cmax) of LOU064 following drug administration at Week 4 and Week 12 .
Time frame: Week 4 and Week 12
Time to Reach the Maximum Concentration (Tmax) of LOU064
Assessment of the time to reach the maximum concentration (Tmax) of LOU064 following drug administration at Weeks 4 and 12
Time frame: Week 4 and Week 12
311 participants enrolled at 82 investigative sites in 17 countries. This Randomized Set included all randomized subjects, regardless of whether or not they actually received study medication. Subjects were analyzed according to the treatment assigned at randomization.
| Milestone | LOU064 Arm 1 | LOU064 Arm 2 | LOU064 Arm 3 | LOU064 Arm 4 | LOU064 Arm 5 | LOU064 Arm 6 | Placebo Arm |
|---|---|---|---|---|---|---|---|
| Started | 44 | 44 | 47 | 44 | 44 | 45 | 43 |
| Randomized set (ran) | 44 | 44 | 47 | 44 | 44 | 45 | 43 |
| Full analysis set (fas) | 44 | 44 | 47 | 44 | 43 | 45 | 42 |
| Safety set (saf) | 44 | 44 | 47 | 44 | 43 | 45 | 42 |
| Completed | 41 | 41 | 45 | 40 | 40 | 36 | 38 |
| Not completed | 3 | 3 | 2 | 4 | 4 | 9 | 5 |
| Withdrew: Adverse event | 0 | 0 | 0 | 3 | 1 | 3 | 0 |
| Withdrew: Lack of efficacy | 1 | 2 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 1 | 1 | 1 | 1 |
| Withdrew: Technical problems | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 1 | 0 | 0 | 1 | 3 |
| Withdrew: Covid-19 pandemic | 0 | 0 | 1 | 0 | 1 | 2 | 0 |
UAS7 score change (LS mean Change) from baseline at Week 4 estimated with a mixed-effect repeated measurement analysis of UAS7 score change from baseline (FAS) The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. The maximum UAS7 value is 42. A higher score indicates worse disease. A negative change score (week 4 score minus Baseline score) indicates improvement.
| Scores on a scale | LOU064 Arm 1 | LOU064 Arm 2 | LOU064 Arm 3 | LOU064 Arm 4 | LOU064 Arm 5 | LOU064 Arm 6 | Placebo Arm |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 4 | -19.10 ± 1.686 | -19.08 ± 1.690 | -14.65 ± 1.624 | -15.99 ± 1.686 | -20.02 ± 1.708 | -18.06 ± 1.691 | -5.44 ± 1.739 |
UAS7 score change (LS mean Change) from baseline at Week 12 estimated with a mixed-effect repeated measurement analysis of UAS7 score change from baseline (FAS)
| Score | LOU064 Arm 1 | LOU064 Arm 2 | LOU064 Arm 3 | LOU064 Arm 4 | LOU064 Arm 5 | LOU064 Arm 6 | Placebo Arm |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12 | -18.11 ± 1.934 | -17.97 ± 1.934 | -15.27 ± 1.850 | -17.67 ± 1.939 | -20.21 ± 1.964 | -17.38 ± 1.985 | -7.87 ± 2.001 |
UAS7=0 and UAS7\<=6 response rate over time by treatment group (non-responder imputation) The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. The maximum UAS7 value is 42. A higher score indicates more severe disease. A negative change score (week 4 score minus Baseline score) indicates improvement.
| Percent of participants | LOU064 Arm 1 | LOU064 Arm 2 | LOU064 Arm 3 | LOU064 Arm 4 | LOU064 Arm 5 | LOU064 Arm 6 | Placebo Arm |
|---|---|---|---|---|---|---|---|
| UAS7=0 | 29.5 (18.7 to 43.0) | 29.5 (18.7 to 43.0) | 29.8 (19.3 to 42.7) | 31.8 (20.6 to 45.3) | 41.9 (29.3 to 55.5) | 26.7 (16.5 to 39.8) | 14.3 (6.7 to 26.7) |
| UAS<=6 | 47.7 (34.8 to 61.0) | 52.3 (39.0 to 65.2) | 38.3 (34.8 to 61.0) | 47.7 (26.6 to 61.0) | 55.8 (42.3 to 68.6) | 42.2 (29.9 to 55.5) | 28.6 (17.7 to 42.3) |
The Weekly angioedema activity score (AAS) is a validated tool to assess occurrence of episodes of angioedema. If the subject reports the occurrence of angioedema ("opening question") with "no", AAS score for this day is 0. If "yes" is the answer to the opening question, the subject will continue to answer questions about the duration, severity and impact on daily functioning and appearance of the angioedema. The AAS7 is a weekly AAS score (AAS7). Minimum and maximum possible AAS7 scores are 0-105. Higher score means more severe disease.
| Weeks | LOU064 Arm 1 | LOU064 Arm 2 | LOU064 Arm 3 | LOU064 Arm 4 | LOU064 Arm 5 | LOU064 Arm 6 | Placebo Arm |
|---|---|---|---|---|---|---|---|
| Cumulative Number of Weeks With an AAS7=0 Response | 10.2 ± 2.33 | 10.5 ± 2.59 | 10.0 ± 3.06 | 9.8 ± 3.05 | 10.3 ± 2.45 | 9.2 ± 3.38 | 8.2 ± 3.50 |
Percentage of subjects with DLQI 0/1 response by treatment group and visit (non-responder imputation) The Dermatology Life Quality Index (DLQI) is a 10-item dermatology-specific quality of life (QoL) measure. Subjects rate their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives thinking about the previous 7 days. An overall score is calculated and ranges from 0 to 30 (higher score meaning worse disease-related QoL). A DLQI score of 0 or 1 means that there is no impact of a skin disease on the patient's life.
| Percentage of participants | LOU064 Arm 1 | LOU064 Arm 2 | LOU064 Arm 3 | LOU064 Arm 4 | LOU064 Arm 5 | LOU064 Arm 6 | Placebo Arm |
|---|---|---|---|---|---|---|---|
| Week 4 | 38.6 (26.5 to 52.2) | 29.5 (18.7 to 43.0) | 29.8 (19.3 to 42.7) | 29.5 (18.7 to 43.0) | 51.2 (37.8 to 64.3) | 33.3 (22.1 to 46.7) | 16.7 (8.4 to 29.4) |
| Week 12 | 34.1 (22.6 to 47.6) | 40.9 (28.6 to 54.4) | 38.3 (26.6 to 51.4) | 40.9 (28.6 to 54.4) | 53.5 (40.0 to 66.5) | 35.6 (24.0 to 48.9) | 28.6 (17.7 to 42.3) |
Summary of DLQI score and change from baseline The Dermatology Life Quality Index (DLQI) is a 10-item dermatology-specific quality of life (QoL) measure. Subjects rate their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives thinking about the previous 7 days. An overall score is calculated and ranges from 0 to 30 (higher score meaning worse disease-related QoL).
| Scores on a scale | LOU064 Arm 1 | LOU064 Arm 2 | LOU064 Arm 3 | LOU064 Arm 4 | LOU064 Arm 5 | LOU064 Arm 6 | Placebo Arm |
|---|---|---|---|---|---|---|---|
| Week 4 | -9.60 ± 7.214 | -8.38 ± 7.241 | -7.18 ± 7.534 | -6.20 ± 6.416 | -9.21 ± 7.994 | -6.15 ± 5.149 | -3.33 ± 8.090 |
| Week 12 | -9.03 ± 6.216 | -7.31 ± 9.392 | -6.60 ± 7.798 | -8.25 ± 6.551 | -8.97 ± 8.891 | -6.27 ± 5.513 | -4.38 ± 6.780 |
Assessment of the area under the blood concentration-time curve (AUC) up to four hours following oral administration at Week 4 and Week 12 .
| hr*ng/mL | LOU064 Arm 1 | LOU064 Arm 2 | LOU064 Arm 3 | LOU064 Arm 4 | LOU064 Arm 5 | LOU064 Arm 6 |
|---|---|---|---|---|---|---|
| Week 4 | 45.2 ± 18.4 | 131 ± 65.4 | 427 ± 314 | 55.9 ± 32.3 | 107 ± 56.8 | 418 ± 246 |
| Week 12 | 41.8 ± 19.5 | 159 ± 151 | 441 ± 313 | 54.4 ± 29.4 | 118 ± 66.6 | 469 ± 240 |
Assessment of the observed maximum blood concentration (Cmax) of LOU064 following drug administration at Week 4 and Week 12 .
| ng/mL | LOU064 Arm 1 | LOU064 Arm 2 | LOU064 Arm 3 | LOU064 Arm 4 | LOU064 Arm 5 | LOU064 Arm 6 |
|---|---|---|---|---|---|---|
| Week 4 | 27.6 ± 13.7 | 67.2 ± 32.7 | 194 ± 142 | 32.2 ± 18.7 | 55.5 ± 34.7 | 196 ± 144 |
| Week 12 | 26.1 ± 14.5 | 80.3 ± 53.9 | 199 ± 137 | 31.2 ± 16.0 | 64.9 ± 42.3 | 219 ± 125 |
Assessment of the time to reach the maximum concentration (Tmax) of LOU064 following drug administration at Weeks 4 and 12
| hours | LOU064 Arm 1 | LOU064 Arm 2 | LOU064 Arm 3 | LOU064 Arm 4 | LOU064 Arm 5 | LOU064 Arm 6 |
|---|---|---|---|---|---|---|
| Week 4 | 1.33 (0.00 to 4.00) | 1.54 (0.00 to 4.00) | 1.52 (0.500 to 3.00) | 0.900 (0.00 to 2.00) | 1.15 (0.00 to 3.02) | 1.52 (0.00 to 3.08) |
| Week 12 | 1.17 (0.00 to 4.08) | 1.48 (0.500 to 4.00) | 1.61 (0.00 to 4.00) | 1.17 (0.500 to 4.00) | 1.32 (0.00 to 4.00) | 1.39 (0.5000 to 4.00) |
Collected over Adverse Events (AEs) and Serious Adverse Events were collected after signature of the informed consent form until 30 days after last dose of study treatment, and up to 16 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LOU064 10mg q.d. | 0/44 (0%) | 1/44 (2.3%) | 15/44 (34.1%) |
| LOU064 35mg q.d. | 0/44 (0%) | 0/44 (0%) | 13/44 (29.5%) |
| LOU064 100mg q.d. | 0/47 (0%) | 0/47 (0%) | 10/47 (21.3%) |
| LOU064 10mg b.i.d. | 0/44 (0%) | 2/44 (4.5%) | 12/44 (27.3%) |
| LOU064 25mg b.i.d. | 0/43 (0%) | 2/43 (4.7%) | 11/43 (25.6%) |
| LOU064 100mg b.i.d. | 0/45 (0%) | 0/45 (0%) | 13/45 (28.9%) |
| Any LOU064 | 0/267 (0%) | 5/267 (1.9%) | 74/267 (27.7%) |
| Placebo | 0/42 (0%) | 0/42 (0%) | 11/42 (26.2%) |
| Event | LOU064 10mg q.d. | LOU064 35mg q.d. | LOU064 100mg q.d. | LOU064 10mg b.i.d. | LOU064 25mg b.i.d. | LOU064 100mg b.i.d. | Any LOU064 | Placebo |
|---|---|---|---|---|---|---|---|---|
| Renal abscessInfections and infestations | 0/44 | 0/44 | 0/47 | 0/44 | 1/43 | 0/45 | 1/267 | 0/42 |
| Chronic spontaneous urticariaSkin and subcutaneous tissue disorders | 0/44 | 0/44 | 0/47 | 1/44 | 1/43 | 0/45 | 2/267 | 0/42 |
| LymphadenopathyBlood and lymphatic system disorders | 1/44 | 0/44 | 0/47 | 0/44 | 0/43 | 0/45 | 1/267 | 0/42 |
| UreterolithiasisRenal and urinary disorders | 0/44 | 0/44 | 0/47 | 1/44 | 0/43 | 0/45 | 1/267 | 0/42 |
| Event | LOU064 10mg q.d. | LOU064 35mg q.d. | LOU064 100mg q.d. | LOU064 10mg b.i.d. | LOU064 25mg b.i.d. | LOU064 100mg b.i.d. | Any LOU064 | Placebo |
|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 7/44 | 2/44 | 2/47 | 4/44 | 4/43 | 4/45 | 23/267 | 3/42 |
| HeadacheNervous system disorders | 1/44 | 7/44 | 4/47 | 3/44 | 6/43 | 5/45 | 26/267 | 6/42 |
| DiarrhoeaGastrointestinal disorders | 2/44 | 0/44 | 0/47 | 4/44 | 0/43 | 1/45 | 7/267 | 2/42 |
| Chronic spontaneous urticariaSkin and subcutaneous tissue disorders | 3/44 | 2/44 | 3/47 | 4/44 | 2/43 | 2/45 | 16/267 | 1/42 |
| Upper respiratory tract infectionInfections and infestations | 1/44 | 2/44 | 2/47 | 0/44 | 3/43 | 0/45 | 8/267 | 1/42 |
| NauseaGastrointestinal disorders | 2/44 | 3/44 | 1/47 | 1/44 | 1/43 | 2/45 | 10/267 | 0/42 |
| PyrexiaGeneral disorders | 3/44 | 0/44 | 0/47 | 2/44 | 1/43 | 0/45 | 6/267 | 0/42 |
Randomized Set included all randomized subjects, regardless of whether or not they actually received study medication. Subjects were analyzed according to the treatment assigned at randomization.
| Age, Categorical(Participants) | LOU064 Arm 1 | LOU064 Arm 2 | LOU064 Arm 3 | LOU064 Arm 4 | LOU064 Arm 5 | LOU064 Arm 6 | Placebo Arm | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 41 | 39 | 44 | 39 | 39 | 41 | 36 | 279 |
| >=65 years | 3 | 5 | 3 | 5 | 5 | 4 | 7 | 32 |
| Age, Continuous(Years) | LOU064 Arm 1 | LOU064 Arm 2 | LOU064 Arm 3 | LOU064 Arm 4 | LOU064 Arm 5 | LOU064 Arm 6 | Placebo Arm | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 42.5 ± 16.04 | 44.0 ± 16.47 | 45.2 ± 13.40 | 46.1 ± 15.21 | 47.4 ± 14.62 | 44.9 ± 13.76 | 45.1 ± 15.24 | 45.0 ± 14.90 |
| Sex: Female, Male(Participants) | LOU064 Arm 1 | LOU064 Arm 2 | LOU064 Arm 3 | LOU064 Arm 4 | LOU064 Arm 5 | LOU064 Arm 6 | Placebo Arm | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 35 | 30 | 39 | 32 | 32 | 29 | 25 | 222 |
| Male | 9 | 14 | 8 | 12 | 12 | 16 | 18 | 89 |
| Race/Ethnicity, Customized(Participants) | LOU064 Arm 1 | LOU064 Arm 2 | LOU064 Arm 3 | LOU064 Arm 4 | LOU064 Arm 5 | LOU064 Arm 6 | Placebo Arm | Total |
|---|---|---|---|---|---|---|---|---|
| White | 36 | 37 | 40 | 36 | 36 | 36 | 35 | 256 |
| Black or African American | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Asian | 7 | 6 | 7 | 7 | 7 | 9 | 7 | 50 |
| Native Hawaiian or Other Pacific | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Multiple | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jun 2019 to primary completion in Jan 2021, 19 months.
Results were first posted in Feb 2022, 1 year 1 month after primary completion. A results delay was requested in Jul 2021.
Of 31 phase 2 interventional studies under Chronic Urticaria, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 19 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Remibrutinib